Drugs /

onvansertib

Back to Drugs List

Overview

NCI Definition [1]:
An orally bioavailable, adenosine triphosphate (ATP) competitive inhibitor of polo-like kinase 1 (PLK1; PLK-1; STPK13), with potential antineoplastic activity. Upon administration, onvansertib selectively binds to and inhibits PLK1, which disrupts mitosis and induces selective G2/M cell-cycle arrest followed by apoptosis in PLK1-overexpressing tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase that is crucial for the regulation of mitosis, and plays a key role in tumor cell proliferation. PLK1 expression is upregulated in a variety of tumor cell types and high expression is associated with increased aggressiveness and poor prognosis.

Clinical Trials

View Clinical Trials for onvansertib

Onvansertib has been investigated in 4 clinical trials, of which 4 are open and 0 are closed. Of the trials investigating onvansertib, 2 are phase 1/phase 2 (2 open) and 2 are phase 2 (2 open).

Deficient DNA Mismatch Repair (dMMR), KRAS Exon 2 Mutation, and KRAS Exon 3 Mutation are the most frequent biomarker inclusion criteria for onvansertib clinical trials.

Colorectal carcinoma, pancreatic ductal adenocarcinoma, and prostate adenocarcinoma are the most common diseases being investigated in onvansertib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Onvansertib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating onvansertib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
nms-p937, nms-1286937, pcm 075, plk1 inhibitor pcm-075, pcm-075, plk-1 inhibitor pcm-075, polo-like kinase 1 inhibitor pcm-075
Drug Categories [2]:
Serine/threonine kinase inhibitors
Drug Target(s) [2]:
PLK1
NCIT ID [1]:
C143162

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.